We ares using our metabolomics technology to develop new clinical diagnostic tests as part of our Precision Medicine product offerings. Our current pipeline is focused on obesity-related metabolic diseases, but the potential exists for diagnostics in a number of therapeutic areas throughout precision medicine.
Using applied metabolomics, we are developing and clinically validating accuGFR as a laboratory-developed test (LDT), based on the gold standard mGFR.
accuGFR may be used for the quantitative determination of glomerular filtration rate (GFR) in serum and plasma patient samples to assist in the diagnosis and treatment of renal diseases.
In studies, accuGFR has shown to be more accurate and precise than the standard of care, creatinine-based eGFR by MDRD (Modification of Diet in Renal Disease).
Pending completion of ongoing development and clinical studies, accuGFR is expected to be commercially available in early 2017.
Non-alcoholic steatohepatitis (NASH) test
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic conditions in the U.S. Non-alcoholic steatohepatitis (NASH) is a more advanced, serious form of liver disease and has a prevalence of 3-5% in the general U.S. population. NASH not only involves excess fat accumulation in the liver, but also chronic inflammation that may lead to progressive hepatic fibrosis (scarring of the liver tissue). This, in turn, can lead to cirrhosis, liver failure and death.
Being able to identify whether a patient with suspected or confirmed liver disease has NASH or not, and/or what level of liver fibrosis the patient has, would provide new ways to manage and control this condition, especially as new drugs and treatment options become commercially available.
To learn more about our growing diagnostics pipeline, contact us.